|KIND-030 – Parvovirus in dogs
|Tirnovetmab (IL31 Antibody) – Atopic dermatitis in dogs
|IL4R Antibody – Atopic dermatitis in dogs
|KIND-510a (feline recombiant epo) – Non-regenerative anemia in cats
|Anti-TNF Antibody* – Inflammatory bowel disease in dogs
Other pipeline candidates in development (partial list) include KIND-bodies, IgE antibody, CD20 antibody, VEGF antibody, and Checkpoint Inhibitors. Anti-TNF antibody will be put on hold post the pilot study pending additional funding or partnering capital.
Pipeline Disclaimer: This material is intended to provide investors with information about KindredBio’s clinical development pipeline and is not intended for promotional purposes.